Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Merck acquisition brings back hope for Harpoon’s trispecific technology

Merck will acquire Harpoon and its DLL3 trispecific for $680M

By Lauren Martz, Executive Director, Biopharma Intelligence
January 8, 2024 11:21 PM UTC

With Merck’s acquisition of trispecific antibody-based therapy company Harpoon, optimism is building around the DLL3 target and its potential to treat some of the most challenging cancer indications. 

Merck & Co. Inc. (NYSE:MRK) will acquire Harpoon Therapeutics Inc. (NASDAQ:HARP) for $23 per share, for a total equity value of about $680 million. The price represents a 118% premium over Friday’s close of $10.55, but well below the company’s 2019 IPO price after a 10:1 reverse stock split in September. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Harpoon Therapeutics Inc.

Merck & Co. Inc.